A new frontier in Drug Design

We aim to revolutionize de way diseases are diagnosed and treated.

The Team

In Short

Aptah is a biotech company that aims to support medical advancements by introducing innovative technologies into the drug discovery process. 

Through Aptah's technology we are able to modulate the spliceosome machinery and thus, the pre-mRNA, which ensures the precise control of the transcription step and modulation of specific gene expression -not only silencing, but also editing the pre-mRNA by hacking the spliceosome machinery.

Get in touch to learn more.

Our Technology

Aptah is focused on treating and diagnosing tauopathy diseases – diseases associated with protein TAU expression. Microtubule-Associated Protein Tau (MAPT) or TAU, is thought to be a major contributor or cause of certain diseases, known as tauopathies, that are characterized by the deposition of abnormal tau protein inside cells, such as neurons and glial in the brain and breast cells. These disorders include Alzheimer’s disease (AD), Progressive Supranuclear Palsy (PSP), some forms of frontotemporal degeneration (FTD), Glioblastoma, Neuroblastoma and Breast Cancer.

Aptah antisense therapy controls TAU expression inside cells, bringing it to a normal level, which stabilizes the cell’s metabolism. Therefore, we are able to reduce its oxidation, inflammation and reproduction rate. 

​

Click below to learn more about the technology behind Aptah, or get in touch to set up a meeting with us.

Get in Touch

BRAZIL

Aptah Biosciences
CFL Square Corporate 
SC401 -5500
Florianópolis, Santa Catarina

+55 48 99982-0154

SWITZERLAND

Minervastrasse 55

8032 Zürich

+41 79 814 34 53